The pharmaceutical and bio industries are rapidly growing and it is becoming increasingly difficult to find competitive new drug candidates. As a result there is a growing demand for investment in huge funds, placing a greater burden on pharmaceutical biotech companies.
Korean startup I.Divine wants to enable these companies to build more competitive new drug and biotechnology portfolios through its performance prediction service solutions.
I.Divine’s performance prediction service solutions based on Artificial Intelligence, has attracted a seed investment from Future Play. The investment amount is confidential.
Helping investors make informed decisions
I.Divine is a company co-founded by Professor Won-Jun Kim, who is serving as the dean of the Graduate School of Technology Management at the Korea Advanced Institute of Science and Technology (KAIST) in December last year with researchers with master’s and doctoral degrees. Currently, I.Divine provides key information to secure competitiveness of bio/pharmaceutical companies, help financial investors build investment portfolios that will maximize the value of their future investments in global markets. The solutions enable companies to build more competitive new drug and biotechnology portfolios .
I.Divine, has accumulated core know-how for predicting technological performance based on long-term research, verifying the high predictive performance of major biotech companies recently approved by the US Food and Drug Administration (FDA) .
I.Divine CEO Won-jun Kim said, “I.Divine’s unique analysis algorithm and AI-based prediction technology can be applied to various high-tech industries based on advanced technology as well as the pharmaceutical industry in the future. It will become a game changer that will change the paradigm of the global investment market.”
“In the past two to three years, investors’ preference for technology stocks and growth stocks has been increasing in the financial market, but the reality is that traditional corporate valuation methods are still being applied to new growth companies,” said Mo Sang-hyeon, an examiner at Future Play, who made this investment. “High-tech companies have very high R&D risk and corporate value depends on performance, so we decided that an integrated analysis of various data was necessary,” he said.